Five key things about the EMA's vaccine decision

vaccine
Credit: Pixabay/CC0 Public Domain

The European Medicines Agency (EMA) will decide on Monday whether to give the green light for the Pfizer-BioNTech coronavirus vaccine within the EU.

The Amsterdam-based regulator brought the decision forward by eight days under pressure from EU states, after Britain and the US approved the jab more quickly.

Here are five key things to know about the decision:

What is the EMA?

The EMA is the regulator for all human and animal medicines in the 27 nations of the European Union. It tests drugs and vaccines for safety and efficacy. Britain is also bound by its rules until the end of the post-Brexit transition period on January 1.

The EMA moved from London to Amsterdam in 2019 after Britain left the EU.

What is it deciding on Monday?

The EMA's Committee for Medicinal Products for Human Use will decide whether to recommend approval for a year-long Conditional Marketing Authorisation (CMA) for Pfizer-BioNTech's vaccine within the EU.

The regulator is allowed to grant a CMA for a medicine during when it can show that the benefits of using it outweigh the risks of speeding up a process that normally takes years.

The EMA has been carrying out a so-called "rolling review" of data from and clinical trials for the vaccine as they come in. Normally it would only review the data after it has all been collected.

A decision on the vaccine by US firm Moderna will be made at a meeting on January 6.

Too slow?

Britain, the United States, Canada, Switzerland, Singapore and Bahrain have all given the for the Pfizer-BioNTech jab, meaning that vaccination could get underway.

The EMA was originally going to decide on the vaccine on December 29 but it brought the date ahead by eight days after Germany and other European states complained about the delay.

If the EMA committee fails to reach a decision on Monday it will hold another meeting on December 29.

What does the EMA say?

The EMA says Britain and the US have only given temporary emergency use authorisation for the vaccine, which requires fewer tests and has to be renewed more frequently.

By contrast, it says the Conditional Marketing Authorisation requires a more rigorous testing procedure, and that it lasts a year, with follow-up tests afterwards.

It is also "paramount" to ensure in the vaccine at a time when scepticism and disinformation are rife, an EMA source told AFP.

Did Brexit make UK quicker?

British ministers said it did. But it later emerged that Britain was still under the EU's rules during the Brexit transition, however it was allowed to opt-out in emergencies.

All EU states were allowed to do so, but made a political decision to go for CMA together to show unity, and to start vaccinations at the same time.

Arguably Brexit had an effect because the EMA took time to work back up to full capacity after its move from London, according to a mid-year report in October.

But there were other factors too, with new EMA chief Emer Cooke only starting the job in November.

The agency also had to deal with a major cyberattack in which documents relating to the Pfizer-BioNTech and Moderna vaccines were stolen, although it insisted the hack didn't affect the timeline.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2020 AFP

Citation: Five key things about the EMA's vaccine decision (2020, December 21) retrieved 19 September 2021 from https://medicalxpress.com/news/2020-12-key-ema-vaccine-decision.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors